A compound of formula (I) is:

##STR00001##

wherein: X.sup.2 represents a —CO—NR.sub.k— group, a —NR′.sub.k—CO— group, a —O— group, a —CO— group, a —SO.sub.2-group, a —CS—NH— group, a —CH.sub.2—NH—, a

##STR00002##

group, or a heterocyclyl, wherein the heterocyclyl is a 5- or 6-membered ring comprising 1, 2, 3 or 4 heteroatoms selected from O, S and/or N; Y.sup.2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a morpholinyl group, optionally substituted by a (C.sub.1-C.sub.4)alkyl group or a trifluoromethyl group, a bridged morpholinyl group, a (C.sub.5-C.sub.11)bicycloalkyl group, an adamantyl group, a piperidinyl group, a (C.sub.1-C.sub.4)alkenyl group, a —PO(OR.sub.a)(OR.sub.b) group, a 5-membered heteroaromatic ring or a —CR.sup.1R.sup.2R.sup.3 group, or any of its pharmaceutically acceptable salt.

A compound of formula (I) is:

##STR00001##

wherein: X.sup.2 represents a —CO—NR.sub.k— group, a —NR′.sub.k—CO— group, a —O— group, a —CO— group, a —SO.sub.2-group, a —CS—NH— group, a —CH.sub.2—NH—, a

##STR00002##

group, or a heterocyclyl, wherein the heterocyclyl is a 5- or 6-membered ring comprising 1, 2, 3 or 4 heteroatoms selected from O, S and/or N; Y.sup.2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a morpholinyl group, optionally substituted by a (C.sub.1-C.sub.4)alkyl group or a trifluoromethyl group, a bridged morpholinyl group, a (C.sub.5-C.sub.11)bicycloalkyl group, an adamantyl group, a piperidinyl group, a (C.sub.1-C.sub.4)alkenyl group, a —PO(OR.sub.a)(OR.sub.b) group, a 5-membered heteroaromatic ring or a —CR.sup.1R.sup.2R.sup.3 group, or any of its pharmaceutically acceptable salt.

The invention relates to the compounds of formula I, formula II, formula III and formula IV or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III or formula IV and methods for the treatment of mucositis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of mucositis and oral mucosal inflammatory or oral infectious diseases.

The invention relates to the compounds of formula I, formula II, formula III and formula IV or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III or formula IV and methods for the treatment of mucositis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of mucositis and oral mucosal inflammatory or oral infectious diseases.

Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Various applications for the described compounds, and combination therapies are described as well.

Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Various applications for the described compounds, and combination therapies are described as well.

The application discloses pharmaceutical compounds of formula I useful for treating CNS diseases wherein m, s, R.sup.1 R.sup.5, R.sup.6 and R.sup.7 are as defined herein.

##STR00001##

The application discloses pharmaceutical compounds of formula I useful for treating CNS diseases wherein m, s, R.sup.1 R.sup.5, R.sup.6 and R.sup.7 are as defined herein.

##STR00001##

Synthetic v6 integrin ligands of Formula I having serum stability and affinity for integrin v6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin v6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include v6 integrin ligands and methods of use are also described.

##STR00001##

The application discloses pharmaceutical compounds of formula I useful for treating CNS diseases wherein m, s, R.sup.1 R.sup.5, R.sup.6 and R.sup.7 are as defined herein.

##STR00001##